Business
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
COPENHAGEN, Denmark, November 03, 2025--Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin’s lymphoma (NHL) subtypes, will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9.
About this update from Genmab A/s
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/b6349e30bb4755da3da3eade8ff05d9d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5qS.5aR8jj_rixv67ignHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b6349e30bb4755da3da3eade8ff05d9d","width":960,"height":280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MRnSDUcDjdYc7c73ffKUkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b6349e30bb4755da3da3eade8ff05d9d","width":1200,"height":350}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignancies","length":236,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"New data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL)","length":163,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results from Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) accepted for oral presentation","length":216,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":615,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, November 03, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin’s lymphoma (NHL) subtypes, will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9.","length":448,"tagName":"p"},{"type":"text","content":"Data from the epcoritamab development program will showcase its expanding clinical profile and potential utility in earlier lines of therapy with a fixed treatment duration. Present...